Toronto, Ontario / TheNewswire / May 21, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have been featured in the Canadian Business Quarterly publication for their revolutionary VMS+ device that makes diagnosing and monitoring heart diseases faster, less expensive and with equivalent accuracy to MRI.
The article "Diagnosing Heart Disease Faster, Safe and More Affordably" along with the podcast interviewing Ventripoint CEO, Dr. George Adams, can be found on the Canadian Business Quarterly website http://thecbq.ca sharing how Ventripoint's novel system has the potential to transform the multi-billion dollar cardiac care industry. As the VMS product line enters the international market, Ventripoint is attracting widespread attention from top cardiologists, investors and distributors.
"The Company is focused on precise, rapid, inexpensive ways to get information on what is happening in all parts of your heart," explains Dr. Adams, who is a pioneer in developing life-improving tools. For the full article and podcast visit: http://thecbq.ca/ventripoint-diagnostics-ltd-ceo-dr-george-adams-ventripoint-diagnostics-tsxvvpt-diagnosing-heart-disease-faster-safer-and-more-affordably/.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release